Melperone exhibits a wide range of bioactivities with varying potencies across different assays. It shows significant potency in inhibiting the Menin-MLL interaction in MLL-related leukemias (44668.4 nM) and acts as a delayed death inhibitor of the malarial parasite plastid after a 96-hour incubation (95.3 nM). It demonstrates potencies in promoting Schwann cell viability (40533.4 nM), involvement in a Schwann cell luciferase assay (16136.6 nM), and blocking the entry of Ebola virus with AC50 values of 6309.6 nM and 6.31 µM in different assays.
Pharmacokinetically, Melperone shows moderate clearance (46.0 mL·min⁻¹·kg⁻¹), a short half-life (3.9 hours), a moderate mean residence time (5.0 hours), and a moderate volume of distribution at steady state (14.0 L·kg⁻¹) in humans after intravenous administration. The compound exhibits moderate hepatotoxicity, characterized by cytolytic, choleostatic, and mixed liver toxicity, though severe hepatitis and chronic liver conditions have not been linked to it.
In antiviral activity assays, Melperone showed mixed results against SARS-CoV-2. It inhibited cytotoxicity in Caco-2 cells by -27.17% at a 10 µM concentration over 48 hours and displayed 16.3% inhibition of the SARS-CoV-2 3CL-Pro protease at 20 µM. However, its IC50 value against SARS-CoV-2 induced cytotoxicity in VERO-6 cells was greater than 20000.0 nM, indicating a relatively weak inhibitory effect. It also demonstrated no significant inhibition of various human transporters (BSEP, MRP2, MRP3, and MRP4) with IC50 values exceeding 133000.0 nM.
Additionally, the compound shows minor inhibition rates for human HDAC6, with 18.11% inhibition in one enzymatic assay and -9.44% in another using different peptide substrates. It has bioactivity involving a primary screen assay using NF54 nanoGlo with a Z score of 0.66 and -6.0% inhibition at 2µM over 72 hours.
Melperone also interacts with several receptors, including DRD1, DRD3, ADRA2A, HTR1A, and others, with AC50 values from 305.0 nM to 12567.5 nM, showing agonistic activity at HTR2B and ADRA1A receptors (AC50 > 30000.0 nM), and antagonist activity at the TBXA2R receptor (AC50 > 30000.0 nM). These interactions suggest potential effects on neurotransmitter systems and hormone receptors..
Note: Summary generated by AI. Data source: ChEMBL 